Ken Griffin Next Cure, Inc. Transaction History

Citadel Advisors LLC

$550 Billion
Q2 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Next Cure, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 58,845 shares of NXTC stock, worth $284,809. This represents 0.0% of its overall portfolio holdings.

Number of Shares

58,845

Previous 1,700 3361.47%

Holding current value

$284,809

Previous $0 Infinity%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$0.27 - $0.68 $8,585 - $21,622	-31,798 Reduced 35.08%	58,845 $27,000
Q1 2025 May 15, 2025	BUY	$0.48 - $0.95 $5,743 - $11,366	11,965 Added 15.21%	90,643 $43,000
Q4 2024 Feb 14, 2025	BUY	$0.77 - $1.54 $17,497 - $34,994	22,724 Added 40.61%	78,678 $60,000
Q3 2024 Nov 14, 2024	SELL	$1.33 - $1.78 $310,017 - $414,910	-233,096 Reduced 80.64%	55,954 $76,000
Q2 2024 Aug 14, 2024	BUY	$1.17 - $2.49 $50,981 - $108,499	43,574 Added 17.75%	289,050 $459,000
Q1 2024 May 15, 2024	SELL	$1.13 - $2.23 $147,322 - $290,734	-130,374 Reduced 34.69%	245,476 $547,000
Q4 2023 Feb 14, 2024	SELL	$1.03 - $1.45 $64,642 - $91,002	-62,760 Reduced 14.31%	375,850 $428,000
Q3 2023 Nov 14, 2023	BUY	$1.29 - $1.84 $58,497 - $83,438	45,347 Added 11.53%	438,610 $565,000
Q2 2023 Aug 14, 2023	SELL	$1.47 - $1.86 $127,278 - $161,046	-86,584 Reduced 18.04%	393,263 $707,000
Q1 2023 May 15, 2023	SELL	$1.46 - $1.83 $61,782 - $77,440	-42,317 Reduced 8.1%	479,847 $710,000
Q4 2022 Feb 14, 2023	BUY	$1.2 - $3.07 $57,680 - $147,565	48,067 Added 10.14%	522,164 $736,000
Q3 2022 Nov 14, 2022	BUY	$2.72 - $5.19 $219,588 - $418,993	80,731 Added 20.52%	474,097 $1.3 Million
Q2 2022 Aug 15, 2022	BUY	$3.38 - $5.27 $11,414 - $17,796	3,377 Added 0.87%	393,366 $1.85 Million
Q1 2022 May 16, 2022	SELL	$4.76 - $6.24 $17,359 - $22,757	-3,647 Reduced 0.93%	389,989 $1.9 Million
Q4 2021 Feb 14, 2022	SELL	$5.7 - $9.1 $17,550 - $28,018	-3,079 Reduced 0.78%	393,636 $2.36 Million
Q3 2021 Nov 15, 2021	SELL	$6.74 - $8.02 $2.12 Million - $2.53 Million	-314,909 Reduced 44.25%	396,715 $2.67 Million
Q2 2021 Aug 16, 2021	SELL	$7.6 - $10.28 $2.65 Million - $3.59 Million	-348,794 Reduced 32.89%	711,624 $5.71 Million
Q1 2021 May 17, 2021	SELL	$9.81 - $13.88 $131,650 - $186,269	-13,420 Reduced 1.25%	1,060,418 $10.6 Million
Q4 2020 Feb 16, 2021	SELL	$9.47 - $12.43 $30,531 - $40,074	-3,224 Reduced 0.3%	1,073,838 $11.7 Million
Q3 2020 Nov 16, 2020	BUY	$8.15 - $21.17 $8.33 Million - $21.6 Million	1,022,303 Added 1866.91%	1,077,062 $9.48 Million
Q2 2020 Aug 14, 2020	SELL	$21.19 - $40.2 $609,318 - $1.16 Million	-28,755 Reduced 34.43%	54,759 $1.17 Million
Q1 2020 May 15, 2020	SELL	$32.32 - $58.37 $23.1 Million - $41.7 Million	-714,192 Reduced 89.53%	83,514 $3.1 Million
Q4 2019 Feb 14, 2020	SELL	$25.0 - $92.22 $3.6 Million - $13.3 Million	-143,851 Reduced 15.28%	797,706 $44.9 Million
Q3 2019 Nov 14, 2019	SELL	$15.73 - $41.6 $2.39 Million - $6.33 Million	-152,225 Reduced 13.92%	941,557 $29 Million
Q2 2019 Aug 14, 2019	BUY	$14.16 - $20.64 $15.5 Million - $22.6 Million	1,093,782 New	1,093,782 $16.4 Million

Others Institutions Holding NXTC

# of Institutions

Shares Held

10.8M

Call Options Held

Put Options Held

View Full List

About NextCure, Inc.

Ticker NXTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,748,800
Market Cap $134M
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...

More about NXTC

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account